Adtralza (tralokinumab)
- Region
- 🇪🇺 EU
- Active substance
- tralokinumab
- Company
- LEO Pharma A/S
- Status
- Authorised
- Therapeutic area
- Dermatitis, Atopic
- CHMP opinion
- Thu 22 Apr 2021
- EU approval
- Thu 17 Jun 2021
- Application
- EMEA/H/C/005255
- ATC
- D11
- Official record
- www.ema.europa.eu
Indication
Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Adtralza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.